Supporting these findings, a previous report showed that stages II and III CRC patients with good prognosis could be categorized into a subtype highly similar to group 2, with features such as MSI, BRAF mutations, and right-sided tumor location [5–7]. This evidence concerns the gene BRAF and neoplasm.